Coming in 2023

When it comes to identifying cancer, there's no such thing as too early. GlycoKnow™ Colon will be available in 2023 as a laboratory-developed risk assessment test that uses glycopeptide and peptide biomarkers to assess the risk of pre-cancerous polyps and colorectal cancer. Now, a single blood draw will be able to put patients with an increased risk of colon cancer on the path to receiving care before a tumor has developed.

GlycoKnow Colon is intended to be complementary to—and not a replacement for—current recommended colorectal cancer testing methods.

Single-tube blood draw

True pre-cancer detection with unmatched advanced adenoma sensitivity

Rapid 10-day
turnaround time

InterVenn’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). Our tests are developed, and the performance characteristics are determined by InterVenn. Our tests have not been cleared or approved by the U.S. Food and Drug Administration. InterVenn’s clinical laboratory is regulated under CLIA to perform high-complexity testing. Our tests are not intended for clinical purposes.

Product Pipeline

Indication Clinical Application Phase
Proof of Concept Classifier Validation LDT Validation Commercially Available
GLORI™ Pelvic Mass Triaging
DAWN™ IO MelanomaImmuno-Therapy Response Prediction
Non-Small Cell Lung Carcinoma (NSCLC)Immuno-Therapy Response Prediction
GlycoKnow™ ColonPre-Malignant Detection, Cancer Prevention
Expected Launch in 2023
Multiple Cancer Early Detection: Breast, Colon, Lung, Pancreas, ProstateEarly Detection
Treatment Monitoring Panel: AutoimmuneDisease Monitoring
Treatment Monitoring Panel: InflammationDisease Monitoring
Treatment Monitoring Panel: Infectious DiseaseDisease Monitoring

Get in touch